5 unknown. 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Unknown 5 |
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis Personalized extended interval dosing of natalizumab, Standard interval dosing - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | Amsterdam UMC, location VUmc | 300 | 2020-02-03 | 2023-04-27 |
| Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Fingolimod, Natalizumab - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | University Hospital Muenster | 15 | 2014-03-01 | 2014-12-25 |
| Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient vitamin A - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | Tehran University of Medical Sciences | 30 | 2011-04-01 | 2012-07-18 |
| Impact of Vitamin A on Multiple Sclerosis (MS) vitamin A, Drug: placebo - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | Tehran University of Medical Sciences | 100 | 2010-02-01 | 2011-08-16 |
| Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Dietary Supplement: vitamin A, placebo - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | Tehran University of Medical Sciences | 20 | 2010-02-01 | 2012-10-12 |
Multiple Sclerosis, Relapsing-Remitting (5) · Multiple Sclerosis (3)
Autoimmune Diseases (5) · Autoimmune Diseases of the Nervous System (5) · Demyelinating Autoimmune Diseases, CNS (5) · Demyelinating Diseases (5) · Immune System Diseases (5) · Nervous System Diseases (5) · Multiple Sclerosis (2)
Vitamin A (2) · Fingolimod Hydrochloride (1) · Natalizumab (1) · retinol palmitate (1)
Tehran University of Medical Sciences (3) · Amsterdam UMC, location VUmc (1) · University Hospital Muenster (1)
Iran (3) · Germany (1) · Netherlands (1)
Sama Bitarafan, MD, PhD student (2) · Luisa Klotz, PD. Dr. med. (1)